2. Peptides
  3. Peptide and Derivatives
  4. Inhibitors and Substrates
  5. LP17 TFA

LP17 TFA  (Synonyms: LQVTDSGLYRCVIYHPP TFA)

Cat. No.: HY-P3400A Purity: 99.85%
COA
SDS
Handling Instructions Technical Support

LP17 (LQVTDSGLYRCVIYHPP) TFA is a BBB-penetrable triggering receptor expressed on myeloid cells (TREM-1) inhibitory peptide. LP17 TFA substantially alleviates ischemia-induced infarction and neuronal injury. LP17 TFA can get access into brain and block TREM-1.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

LP17 TFA

LP17 TFA Chemical Structure

Size Price Stock Quantity
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

Other Forms of LP17 TFA:

LP17 TFA Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

LP17 (LQVTDSGLYRCVIYHPP) TFA is a BBB-penetrable triggering receptor expressed on myeloid cells (TREM-1) inhibitory peptide. LP17 TFA substantially alleviates ischemia-induced infarction and neuronal injury. LP17 TFA can get access into brain and block TREM-1[1].

IC50 & Target

TREM-1[1]
In Vitro

LP17 (1 or 10 μM; 24 h) TFA substantially decreases mRNA levels of pro-inflammatory cytokines and chemokines after reoxygenation and remarkably attenuates extracellular protein levels of IL-1β and IL-18 in a microglia oxygen-glucose deprivation (OGD) model[1].
LP17 (10 μM; 24 h) TFA interacts with microglial SYK[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

LP17 TFA Related Antibodies

RT-PCR[1]

Cell Line: Primary microglia
Concentration: 1 or 10 μM
Incubation Time: 24 h
Result: Decreased mRNA levels of NLRP3, IL-1β, IL-18, IL-6, CD16, CD32, iNOS, MCP-1, CXCL-1, and CXCL-2 after reoxygenation.

Western Blot Analysis[1]

Cell Line: Primary microglia
Concentration: 10 μM
Incubation Time: 24 h
Result: Suppressed ischemia/reperfusion-induced increments in CARD9, p-p65 in CARD9/NF-κB signaling and NLRP3, ASC, cleaved caspase-1, mature IL-1β, and mature IL-18 in NLRP3/caspase-1 signaling in a microglia oxygen-glucose deprivation (OGD) model.
In Vivo

LP17 (0.5 or 1 mg/kg; intranasal; daily for 3 days) TFA alleviates ischemia-induced infarction and neuronal injury in mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Adult male C57BL/6J mice (20-25 g), mice cerebral ischemia/reperfusion (I/R) model induced by middle cerebral artery occlusion (MCAO)[1]
Dosage: 0.5 mg/kg or 1 mg/kg
Administration: Intranasal administration, once daily for 3 consecutive days after MCAO
Result: Abolished ischemia-induced TREM-1 elevation at 1 mg/kg.
Significantly reduced infarct volume by 27.3%, induced a markedly reduction in TUNEL positive cells and FJC positive neurons at 1 mg/kg.
Rescued neurological deficits and cognitive dysfunction of MCAO mice. Inhibited microglial M1 polarization and neutrophil infiltration.
Molecular Weight

1961.24 (free base)

Formula

C89H137N23O25S.xC2HF3O2
Appearance

Solid

Color

White to off-white

Sequence

Leu-Gln-Val-Thr-Asp-Ser-Gly-Leu-Tyr-Arg-Cys-Val-Ile-Tyr-His-Pro-Pro
Sequence Shortening

LQVTDSGLYRCVIYHPP
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Sealed storage, away from moisture and light

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility
In Vitro: 

H2O : 3.33 mg/mL (Need ultrasonic)

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation

Purity: 99.85%

SDS (252 KB)

COA (250 KB) LCMS (93 KB)

Handling Instructions (2659 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

LP17 TFA Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

LP17LQVTDSGLYRCVIYHPPLP 17LP-17OthersTREM-1 inhibitory peptideischemia-induced infarctionneuronal injurynervous systemInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
LP17 TFA
Cat. No.:
HY-P3400A
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.